Table 3.
Sub-group meta-analysis of study-level factors associated with LVSD
| Analysis | Subgroup | Studies | Pooled prevalence | 95% CI | I² |
|---|---|---|---|---|---|
| Overall | All studies | 20 | 6.00% | 3.00–12.00 | 95.1% |
| ART era | Pre-ART/early ART | 4 | 27.80% | 15.10–45.40 | 94.2% |
| ART era | 16 | 3.60% | 2.00–6.40 | 88.8% | |
| Method* | FS | 7 | 18.00% | 8.40–34.50 | 92.7% |
| EF | 12 | 2.70% | 1.60–4.50 | 70.9% | |
| Study quality | Low Risk | 14 | 3.20% | 1.40–6.96 | 96.1% |
| Moderate Risk | 6 | 17.90% | 11.50–26.80 | 76.5% | |
| ART coverage | < 80% on ART | 5 | 12.80% | 4.20–32.60 | 96.4% |
| ≥ 80% on ART | 12 | 2.60% | 1.40–4.70 | 74.4% | |
| AIDS proportion | < 50% AIDS | 9 | 11.30% | 5.20–22.70 | 94.2% |
| ≥ 50% AIDS | 4 | 1.73% | 0.10–18.60 | 96.3% |
*Total number of studies for Method is 19 as one study which applied a stricter definition for LVSD (FS < 25%) was included in the main analysis but excluded from the subgroup analysis